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XIAP impairs Smac release from the mitochondria
during apoptosis
L Flanagan1, J Sebastia`1, LP Tuffy1, A Spring1, A Lichawska1, M Devocelle2, JHM Prehn1 and M Rehm*,1
X-linked inhibitor of apoptosis protein (XIAP) is a potent inhibitor of caspases 3, 7 and 9, and mitochondrial Smac (second
mitochondria-derived activator of caspase) release during apoptosis inhibits the activity of XIAP. In this study we show that
cytosolic XIAP also feeds back to mitochondria to impair Smac release. We constructed a fluorescent XIAP-fusion protein by
labelling NH2- and COOH-termini with Cerulean fluorescent protein (C-XIAP-C). Immunoprecipitation confirmed that C-XIAP-C
retained the ability to interact with Smac and impaired extrinsically and intrinsically activated apoptosis in response to tumour
necrosis factor-related apoptosis-inducing ligand/cycloheximide and staurosporine. In C-XIAP-C-expressing cells, cytochrome c
release from mitochondria proceeded normally, whereas Smac release was significantly prolonged and incomplete. In addition,
physiological expression of native XIAP prolonged or limited Smac release in HCT-116 colon cancer cells and primary mouse
cortical neurons. The Smac-binding capacity of XIAP, but not caspase inhibition, was central for mitochondrial Smac retention,
as evidenced in experiments using XIAP mutants that cannot bind to Smac or effector caspases. Similarly, the release of a Smac
mutant that cannot bind to XIAP was not impaired by C-XIAP-C expression. Full Smac release could however be provoked by
rapid cytosolic C-XIAP-C depletion upon digitonin-induced plasma membrane permeabilization. Our findings suggest that
although mitochondria may already contain pores sufficient for cytochrome c release, elevated amounts of XIAP can selectively
impair and limit the release of Smac.
Cell Death and Disease (2010) 1, e49; doi:10.1038/cddis.2010.26; published online 3 June 2010
Subject Category: Cancer
A balance between cell proliferation and apoptotic cell death is
of vital importance for all metazoans during both development
and adulthood. Consequently, loss- or gain-of-function muta-
tions in genes regulating apoptosis have been implicated
in various proliferative and degenerative diseases. In most
scenarios, apoptosis execution depends on proteases of the
caspase family. During apoptosis, initiator caspase-9 and
executioner caspases 3 and 7 are activated in response to
cytochrome c (cyt-c) release from mitochondria into the
cytosol. Activation of the executioner caspases proceeds in a
rapid all-or-none manner,1 but can be inhibited if the main
inhibitor of these caspases, X-linked inhibitor of apoptosis
protein (XIAP), is present in concentrations above a critical
threshold.2,3 XIAP has been reported to prevent execution of
apoptotic cell death in both physiological and pathophysiolo-
gical scenarios. Upon cell differentiation, XIAP contributes to
the high apoptosis resistance of various postmitotic cell types
such as neurons, cardiomyocytes and myotubes.4–6 Similarly,
XIAP expression was shown to increase with advancing
tumour stages and is associated with a poor prognosis in
prostate and renal cancers, as well as acute myeloid
leukaemias.7–9 In contrast, XIAP deficiency in humans was
associated with excessive lymphocyte apoptosis, which
resulted in reduced numbers of natural killer T cells.10
XIAP comprises three baculoviral IAP repeat domains
(BIR1–3), as well as a zinc-finger RING (really interesting new
gene) domain, which exerts E3 ubiquitin ligase activity. The
dimerization of caspase-9 monomers to yield the active
caspase-9 conformation is inhibited by the BIR3 domain of
XIAP through binding to the caspase-9 dimerization inter-
face.11 Executioner caspases 3 and 7 instead are inhibited by
a region preceding the BIR2 domain. This region occupies the
substrate-binding groove of executioner caspases 3 and 7,
but requires further interactions of the effector caspases with
the BIR2 domain to stabilize this inhibition.12
The main antagonist of XIAP is the second mitochondria-
derived activator of caspases (Smac). Dimeric Smac sterically
and/or competitively occludes the caspase 3, 7 and 9 binding
sites of XIAP and thereby can pave the way for efficient cell
death execution.13,14 Smac also binds to other IAPs, such
as livin/ML-IAP, Bruce/Apollon, cIAPs 1 and 2,15–17 which
interfere with caspase-mediated cell death and/or have
additional roles in pro-survival and proliferation signalling.
During apoptosis, Smac, similar to cyt-c, is released into the
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cytosol through pores formed by activated Bax or Bak
proteins. Bax/Bak pores seem to be rather unspecific towards
the proteins they release. Using single cell imaging, we and
others have provided evidence that cyt-c, Smac and other
soluble mitochondrial intermembrane space proteins are
released simultaneously during apoptosis,18,19 although
Smac may be released with slightly slower kinetics.19 On
the basis of the assumption that cytosolic proteins are able to
enter the mitochondrial intermembrane space once Bax/Bak
pores are formed, we investigated whether physiological or
elevated XIAP levels can affect the kinetics or the extent of
Smac release.
Results
Generation and molecular characterization of a
fluorescent XIAP fusion protein. To investigate the
influence of XIAP on apoptotic signalling, we generated a
fluorescent XIAP fusion protein to unambiguously identify
transfected cells within the analysed populations. For highly
sensitive detection of XIAP expression, we fused XIAP at both
NH2 and COOH termini with Cerulean fluorescent protein, a
blue-shifted variant of green fluorescent protein (Figure 1a)
that surpasses the more regularly used cyan fluorescent pro-
tein in fluorescence quantum efficiency and photostability.20
As XIAP can be cleaved by caspase-3, caspase-3-deficient
MCF-7 breast cancer cells were initially used as a model
system to obtain unperturbed information on the function
of the full-length XIAP protein. Cerulean-XIAP-Cerulean
(C-XIAP-C) was expressed at the expected molecular
weight of approximately 109 kDa (Figure 1b) and expression
levels of native XIAP were not affected by C-XIAP-C
expression (Figure 1b). On average, the amounts of
C-XIAP-C expressed resembled twice the amount of native
XIAP (Figure 1c). Cells presenting low fluorescence intensities
were therefore selected in subsequent imaging experiments
to avoid excessive overexpression scenarios. C-XIAP-C
was predominantly localized in the cytosol, and transfected
MCF-7 cells morphologically did not differ noticeably from
untransfected cells or control cells expressing Cerulean only
(Figure 1d). C-XIAP-C efficiently blocked effector caspase-
dependent apoptosis execution, as evidenced by reduced cell
surface exposure of phosphatidylserine in response to tumour
necrosis factor-related apoptosis-inducing ligand/cyclo-
heximide (TRAIL/CHX) and broad-spectrum kinase inhibitor
staurosporine (STS), drugs that target either the extrinsic or
intrinsic apoptosis pathways, respectively (Figure 1e and f).
Additional control experiments showed that the anti-apoptotic
potential of C-XIAP-C was comparable to native XIAP
(Figure 1g), and that C-XIAP-C could interact with its physio-
logical binding partner and antagonist Smac (Figure 1h), as
well as with Smac-yellow fluorescent protein (YFP) fusion
proteins (Supplementary Figure 1) that were used later in this
study. We therefore concluded that the C-XIAP-C probe
reliably reflected the key features of native XIAP during
apoptosis signalling.
Attempts at generating proliferating MCF-7 cell clones that
stably expressed C-XIAP-C or elevated amounts of native
untagged XIAP failed. Indeed, when observing MCF-7 cells
expressing C-XIAP-C for up to 2 days, we noticed that these
cells ceased to proliferate, whereas control cells expressing
Cerulean continued to divide (Figure 2a–d). These results
suggested that elevated XIAP expression induced cell cycle
arrest in MCF-7 breast cancer cells, a finding previously also
reported for human endothelial cells.21 We therefore
concluded that selection for clonal populations with stable
ectopic XIAP expression is either impossible or could yield
mutants with a further deregulated cell cycle. For a quantita-
tive single-cell analysis, fluorescently labelled XIAP variants
were therefore required to unambiguously identify cells with
elevated XIAP expression after lipotransfection.
Time-lapse fluorescence imaging indicates that
C-XIAP-C impairs the mitochondrial release of Smac
but not cyt-c. We next analysed the release of the pro-
apoptotic mitochondrial intermembrane space proteins cyt-c
and Smac in the presence of C-XIAP-C expression. As cells
within a population do not commit to mitochondrial permea-
bilization synchronously, we resorted to single-cell time-lapse
imaging to investigate the real-time kinetics of the release
processes. To this end we used cyt-c and Smac fluorescent
fusion proteins, which were previously shown to reliably
show the behaviour of the native proteins.18,19,22 After
apoptosis induction by TRAIL/CHX, cyt-c-green fluorescent
protein (GFP) was released from mitochondria and
distributed homogeneously throughout the cytosol in
both Cerulean- and C-XIAP-C-expressing cells (Figure 3a
and b). Plotting the release kinetics indicated that cyt-c-GFP
release, once initiated, proceeded rapidly without differing
noticeably between cells expressing Cerulean or C-XIAP-C
(Figure 3c and d). Interestingly however, Smac-YFP release
was impaired in cells expressing C-XIAP-C, whereas control
cells expressing Cerulean released Smac-YFP fully (Figure 3e
and f). Smac-YFP release from mitochondria of Cerulean-
expressing cells progressed swiftly, whereas the release in the
presence of C-XIAP-C expression was significantly prolonged
and incomplete, as indicated by higher values in the cellular
fluorescence S.D. after release (Figure 3g and h).
Pooling the data from all cells measured for statistical
comparison further substantiated these observations.
Although cyt-c-GFP release durations did not significantly
differ between Cerulean- or C-XIAP-C-expressing cells,
C-XIAP-C expression significantly extended Smac-YFP
release up to a duration of approximately 90 min (Figure 4a).
Comparing the cellular fluorescence homogeneities after
release as a measure for the extent of cyt-c-GFP or Smac-
YFP redistribution indicated that C-XIAP-C expression selec-
tively prevented Smac-YFP from being fully released from
mitochondria (Figure 4b and c). Similarly, we detected that
Smac-YFP release was also prolonged and incomplete in
C-XIAP-C-expressing MCF-7 cells during intrinsic apoptosis
signalling induced by 1 mM STS (Figure 4d and e).
We next performed immunofluorescence staining of
TRAIL/CHX or STS-treated MCF-7 cells to investigate
whether differential release patterns for cyt-c or Smac could
phenotypically also be observed for the native proteins.
Cells expressing Cerulean co-released both cyt-c and
Smac (Figure 4f). In contrast, in C-XIAP-C-expressing
cells we could indeed identify that Smac was partially retained
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in the mitochondria, whereas cyt-c was fully released in
response to both TRAIL/CHX and STS (Figure 4g). When
applying an edge detection algorithm to investigate cells for
inhomogeneities in subcellular protein distributions, we found
that in control cells XIAP was homogeneously distributed
within the cytosol, whereas areas with slightly increased XIAP
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Figure 1 Characterization of a fluorescent XIAP fusion protein. (a) The generated XIAP fusion protein (C-XIAP-C). Full-length XIAP was fused at both NH2 and COOH
termini with Cerulean fluorescent protein to allow for highly sensitive XIAP detection. (b) Parental MCF-7 cells as well as MCF-7 cells transiently transfected to express
Cerulean or C-XIAP-C were probed with antibodies against Cerulean or XIAP. C-XIAP-C was detected at its expected molecular weight of 109 kD. a-Tubulin served as loading
control. (c) Comparative quantification of XIAP and C-XIAP-C expression in MCF-7 cells. Densitometry was performed on digitally recorded 12-bit images of immunoblots
probed with a XIAP antibody. Data are meansþ S.E.M. from n¼ 3 detections. (d) Expression of C-XIAP-C does not affect cellular morphology. Cells were imaged 24 h after
transfection. Cerulean fluorescence was found throughout the cell, whereas C-XIAP-C was predominantly found in the cytosol. Scale bar¼ 10mm. (e, f) C-XIAP-C inhibits
apoptosis. MCF-7 cells transiently transfected to express Cerulean or C-XIAP-C were exposed to TRAIL/CHX (100 ng/ml plus 1 mg/ml) or STS (1 mM) for the indicated times
and analysed by flow cytometry. Apoptosis was measured as the percentage of annexin V-FITC-positive/PI-negative cells. Addition of caspase inhibitor zVAD-fmk (50 mM)
indicated that the apoptotic response to TRAIL/CHX or STS was caspase dependent. Data are shown as meanþ S.D. from n¼ 3 samples. *Significant differences (Po0.05;
one-way ANOVA and subsequent Tukey’s test). Experiments were repeated with similar results. (g) C-XIAP-C has an anti-apoptotic potency comparable to native XIAP.
MCF-7 cells transiently transfected to express Cerulean, XIAP or C-XIAP-C were exposed to TRAIL/CHX (100 ng/ml plus 1 mg/ml) for 4 h and analysed by flow cytometry.
Apoptosis was measured as the percentage of annexin V-FITC-positive/PI-negative cells. Data are shown as meanþ S.D. from n¼ 3 independent samples. *Significant
induction of apoptosis (Po0.05); NS, not significant (one-way ANOVA and subsequent Tukey’s test). Experiment was repeated with similar results. (h) C-XIAP-C interacts
with Smac. XIAP-deficient HCT-116 cells transiently transfected to express C-XIAP-C were lysed and immunoprecipitation was performed in native cell extracts with a Smac
bait antibody. After western blotting, C-XIAP-C was detected with an antibody directed against XIAP
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concentrations could be detected after TRAIL/CHX or
STS treatment (Supplementary Figure 2A). These areas
resembled edges detected for cells in which Smac release
was incomplete (Supplementary Figure 2B), suggesting that
after mitochondrial outer membrane permeabilization
(MOMP), a fraction of XIAP might accumulate at or within
mitochondria.
Physiological XIAP expression can impair Smac
release. We previously identified that native XIAP expres-
sion in parental HCT-116 colon cancer cells causes a
pronounced delay between MOMP and subsequent effector
caspase activation.23 We therefore hypothesized that in
these cells native XIAP might be sufficiently highly expressed
to also influence Smac release. When comparing Smac-YFP
release between parental and XIAP-deficient HCT-116 cells,
we found that in the absence of XIAP, Smac-YFP release
proceeded significantly faster during both extrinsic and
intrinsic apoptosis (Figure 5a and c). The extent of Smac-
YFP release was similar in all scenarios, indicating that the
amounts of XIAP expressed in HCT-116 cells were not high
enough to retain Smac efficiently inside mitochondria (Figure
5b and d). Physiological XIAP expression was described to
exert a particularly prominent role in preventing apoptosis
execution in differentiated neurons.5 Smac-YFP release in
primary mouse cortical neurons indeed proceeded slowly
and was incomplete, but could be accelerated significantly
and brought to completion by brief pre-treatment of neuronal
cultures with an IAP-antagonizing peptide (Figure 5e and f).
These results therefore indicate that native XIAP can impair
Smac release and that physiological IAP expression can limit
Smac release in primary neurons.
Impairment of Smac release during extrinsic or intrinsic
apoptosis requires direct Smac–XIAP interaction. We
next investigated what binding capacities of XIAP were
crucial for the impaired Smac release that we observed in the
presence of C-XIAP-C. To this end we expressed XIAP
variants not interacting with either Smac or effector caspases
in HCT-116 cells deficient of native XIAP. Consistent with
our findings in MCF-7 cells, C-XIAP-C expression resulted
in significantly prolonged and incomplete Smac release in
response to both TRAIL/CHX and STS (Figure 6a–c). Using
a C-XIAP-C W310A mutant to abrogate Smac binding13
restored rapid and complete Smac release as observed in
control cells (Figure 6a–c). We also introduced a D148A
mutation into C-XIAP-C to express a variant that can still bind
to Smac but cannot efficiently inhibit effector caspases.12,24
Presence of C-XIAP-C D148A resulted in prolonged Smac
release, comparable to cells expressing wild-type C-XIAP-C
(Figure 6a). In response to intrinsic apoptosis induced by
STS, C-XIAP-C D148A was as potent as wild-type C-XIAP-C
in preventing full Smac release (Figure 6b). In response
to TRAIL/CHX, C-XIAP-C D148A was slightly less efficient
in maintaining Smac inside mitochondria at late times
(Figure 6b), probably because of caspase-8 directly
activating caspase-3 and the latter cleaving XIAP between
the BIR2 and 3 domains into fragments that can no longer
bind efficiently to Smac.25 However, as C-XIAP-C D148A-
expressing cells continued to proceed through apoptosis
execution in response to TRAIL/CHX, we cannot exclude
that morphological changes such as cellular shrinkage
and blebbing also contributed to this reading. Expressing
C-XIAP-C or the W310A mutant in HeLa cervical cancer
at concentrations not fully inhibiting apoptosis execution
similarly showed that the Smac-binding capacity of XIAP was
critical to prolonging Smac release and to cause
mitochondrial Smac retention (Figure 6d and e).
We also expressed a Smac mutant that cannot bind to
XIAP (Smac(A54M)-YFP) in Smac-deficient HCT-116 cells,
and investigated its release in the presence of Cerulean or
C-XIAP-C expression. Irrespective of whether C-XIAP-C
was present or not, we observed a complete and rapid
release of Smac(A54M)-YFP in all cells investigated
(Figure 7a–c). In addition, we compared the release kinetics
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Figure 2 Expression of C-XIAP-C impairs cell proliferation. (a, b) Cell
proliferation was observed by fluorescence microscopy of Cerulean- or C-XIAP-C-
expressing MCF-7 cells. Comparison of cell numbers after 24 h suggested that
proliferation of C-XIAP-C-expressing cells was impaired. Scale bars¼ 20mm.
(c, d) Identical fields of view of Cerulean- or C-XIAP-C-expressing cells were
re-examined after 24 and 48 h and the number of fluorescent cells were recorded.
Quantifications from n¼ 3 experiments indicated that Cerulean-expressing MCF-7
cells continued to proliferate whereas expression of C-XIAP-C induced growth
arrest. Error bars represent S.E.M.
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of Smac-YFP to those of a spectrally compatible intermem-
brane space red fluorescent protein (RFP) that uses the same
import mechanism as the immature Smac pro-form but cannot
interact with XIAP (IMS-RP). Both proteins were co-released
during TRAIL/CHX-induced apoptosis (Dt o2 min; not
shown). The release duration of Smac-YFP was significantly
increased at conditions of elevated XIAP expression, whereas
the duration of IMS-RP release was not affected (Supple-
mentary Figure 3). These findings showed that at elevated
XIAP expression, mitochondrial intermembrane space pro-
teins are still co-released but that binding of XIAP to
Smac significantly modulates the kinetics and amounts of
Smac release.
Mitochondrial retention of Smac by C-XIAP-C requires
cellular integrity. Our above results indicated that XIAP
may retain Smac inside mitochondria that already underwent
MOMP. We therefore hypothesized that in cell populations
induced to undergo apoptosis, individual cells could be
identified that apparently had not yet released Smac-YFP in
significant amounts, but might spontaneously do so upon
reducing the cytosolic C-XIAP-C concentration. In contrast,
in untreated cells, Smac-YFP would be expected to remain
inside the mitochondrial compartment.
To rapidly reduce the C-XIAP-C concentration, we selec-
tively permeabilized the plasma membrane of MCF-7 cells on
stage of the microscope by addition of mild extracellular
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Figure 3 Cyt-c-GFP and Smac-YFP release in the presence of C-XIAP-C expression. (a, b) A Cerulean-expressing or a C-XIAP-C-expressing MCF-7 cell releasing cyt-c-
GFP in response to 100 ng/ml TRAIL plus 1mg/ml CHX is shown. Upon release, cyt-c-GFP fluorescence redistributed from the mitochondria into the cytosol. Time indicates
minutes after stimulus addition. Scale bar¼ 10mm. (c, d) Temporal profiles of cyt-c-GFP release in Cerulean-expressing (c) or C-XIAP-C-expressing (d) MCF-7 cells. The
cyt-c-GFP release process was plotted as the change in cellular fluorescence S.D. and shown for three representative cells. Release onset was set to time zero. Cyt-c-GFP
release proceeded rapidly. A total of n¼ 10 Cerulean-expressing cells or n¼ 19 C-XIAP-C-expressing cells from 4 or 6 experiments were analysed, respectively.
(e) A Cerulean-expressing MCF-7 cell releasing Smac-YFP in response to 100 ng/ml TRAIL plus 1 mg/ml CHX is shown. Upon release, Smac-YFP fluorescence redistributed
from the mitochondria to the cytosol. Time indicates minutes after stimulus addition. Scale bar¼ 10mm. (f) A C-XIAP-C-expressing MCF-7 cell releasing Smac-YFP in
response to 100 ng/ml TRAIL plus 1 mg/ml CHX is shown. Smac-YFP fluorescence redistribution from the mitochondria to the cytosol seemed incomplete even after prolonged
times. Time indicates minutes after stimulus addition. Scale bar¼ 10mm. (g, h) Temporal profiles of Smac-YFP release in Cerulean-expressing (g) or C-XIAP-C-expressing
(h) MCF-7 cells. The Smac-YFP release process was plotted as the change in cellular fluorescence S.D. and shown for three representative cells. Release onset was set to
time zero. Smac-YFP release in C-XIAP-C-expressing cells was slow and the loss in fluorescence S.D. was less pronounced when compared with Cerulean-expressing cells.
A total of n¼ 13 Cerulean-expressing cells or n¼ 17 C-XIAP-C-expressing cells from 6 or 8 experiments were analysed, respectively
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Figure 4 Elevated XIAP expression results in significantly prolonged and submaximal release of Smac. (a) The duration of cyt-c-GFP or Smac-YFP release in response to
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significantly prolonged in cells expressing C-XIAP-C. Error bars represent S.E.M. *Po0.05, Student’s t-test. (e) Comparison of amounts of Smac-YFP released in response to
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concentrations of digitonin (see Materials and Methods). In
untreated cells, no mitochondrial Smac release was observed
upon plasma membrane permeabilization (Figure 8a and c).
In cells that were pre-treated with TRAIL/CHX for 4 h, the
depletion of C-XIAP-C was instead accompanied by a
simultaneous release of Smac from the mitochondria in all
cells investigated (Figure 8b and d). These results were
further substantiated after quantification and comparison of
Smac release in the two scenarios (Figure 8e). These results
therefore indicated that mitochondria in pre-treated cells had
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already undergone outer membrane permeabilization and
that prolonged mitochondrial retention of Smac-YFP was
dependent on sufficiently high levels of cytosolic XIAP.
Digitonin-based plasma membrane permeabilization is an
initial step for biochemical cell fractionation and is widely
used to analyse changes in the subcellular localization of
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mitochondrial proteins during apoptosis. As our results
above indicated, classical biochemical fractionation seems
inappropriate to investigate the XIAP-dependent mitochon-
drial retention of Smac after MOMP. Indeed, immunoblots
from mitochondria-containing pellet fractions showed identi-
cal patterns of mitochondrial Smac loss between Cerulean-
or C-XIAP-C-expressing cells (Figure 8f, pellet fraction),
confirming that the Smac-retaining function of XIAP is situated
downstream of MOMP. It is noteworthy that the amounts of
Smac that could be detected in cytosolic extracts subsequent
to cell disruption were significantly higher in C-XIAP-C-
expressing cells (Figure 8f, cytosolic fraction). This finding
suggested that the additional mitochondrial Smac that is
released upon cell disruption was inaccessible to the
otherwise highly efficient cytosolic proteasomal degradation
of Smac.26,27 Correspondingly, the higher amounts of Smac
detected were not accompanied by similar increases in
signals that corresponded to the molecular weights of poly-
ubiquitinated cytosolic Smac (Figure 8f).
Discussion
We identified that the presence of XIAP can prolong and limit
the release of Smac from the mitochondria during extrinsically
and intrinsically induced apoptosis. Our data indicate that this
function of XIAP is primarily mediated by its Smac-binding
capacity and is situated downstream of the permeabilization
of the outer mitochondrial membrane.
As mitochondrial Bax/Bak pores are not selective towards
the proteins passing through,18,19 it is conceivable that apart
from cyt-c and Smac leaving the mitochondria, XIAP may
diffuse into Bax/Bak pores or gain access to the intermem-
brane space. Similarly, it was previously also shown that
active effector caspases might enter the intermembrane
space after pore formation.28 Mature Smac has a molecular
weight of 21 kDa and dimerizes at physiological
conditions.29,30 Smac dimers migrate at an apparent mole-
cular weight of approximately 100 kDa during native gel
electrophoresis because of their non-globular, arch-shaped
conformation.29,30 XIAP, which has a molecular weight of
56 kDa, similarly dimerizes at elevated concentrations
through its BIR1 domain.31 Stoichiometrically, native XIAP*S-
mac aggregates that may form at the outer mitochondrial
membrane or within the intermembrane space therefore
could constitute two and four molecules of XIAP and Smac,
respectively. Such a protein complex may reach a size that no
longer passes efficiently through Bax/Bak pores. Cyt-c
instead, which is co-released with Smac, is a small (12 kDa)
and predominantly monomeric protein that only transiently
binds to and activates its cytosolic binding partner Apaf-1.
Although it has been shown that Bax, in cooperation with
cardiolipin, can form pores sufficient to release megadalton
dextran molecules from liposomes,32 our data indicate that
inside living cells pore sizes may be limited. Limitations could
potentially arise from the restricted availability of cardiolipin in
the outer mitochondrial membrane and/or sterical hindrance
through other intramembranous or membrane-associated
proteins.33 In cells with deficiencies in pore forming Bcl-2
family members, the release of Smac has also been shown to
be more readily impaired than cyt-c release,34 suggesting that
scenarios may exist in which limitations in Bax/Bak amounts
restrict efficient Smac release.
XIAP also exerts functions besides interacting with Smac
and caspases 9, 3 and 7. For example, XIAP was shown to
regulate bone morphogenic factor signalling, tumour necrosis
factor signalling, transforming growth factor-b signalling as
well as signalling through NOD-like receptors.31,35–37 These
functions are mediated by interactions through the BIR1 or
BIR2 domains as well as by ubiquitination of binding partners
through the XIAP RING domain, and can induce kinase
signalling cascades and, at least when overexpressed, NF-kB
activation. A role for XIAP in inducing NF-kB-mediated cell
cycle arrest was previously described in human endothelial
cells and attributed to NF-kB-dependent induction of inhibitors
of cyclin-dependent kinases p21 and p27, as well as to a
downregulation of cyclins A and D.21 Interestingly, we found
that elevated XIAP expression also blocked cell cycle
progression in MCF-7 breast cancer cells. In addition to
caspase inhibition, elevated levels of XIAP therefore may
induce a safeguard mechanism that prevents the proliferation
of highly apoptosis-resistant and therefore potentially danger-
ous cells. This would suggest that tumours showing an
overexpression of XIAP would very likely also present an
overactivation or deregulation of cyclin-dependent kinase
pathways, a feature that indeed is characteristic for many
types of human cancers. We cannot fully exclude that
induction of NF-kB signalling by XIAP contributed to the
limited Smac release that we observed. However, as plasma
membrane permeabilization abrogated the mitochondrial
retention of Smac within seconds, we suggest that impaired
Smac release is an immediate consequence of sufficiently
high cytosolic XIAP concentrations rather than an indirect
effect of alternative XIAP-dependent signalling. This is further
supported by the Smac-binding capacity of XIAP being critical
for limiting the release of Smac in our experiments.
It needs to be mentioned that if the entire fraction of
mitochondrially retained Smac could still bind XIAP, which
enters through pores, then mitochondrial Smac retention
would not potentiate apoptosis inhibition. However, a
pronounced mitochondrial accumulation of high amounts of
XIAP could not be detected. Cells with incomplete Smac
release only presented with a partial, if detectable, redistribu-
tion of XIAP to mitochondria. The lack of pronounced
mitochondrial XIAP accumulation is consistent with a model
in which a sufficiently high XIAP influx gradient counters Smac
efflux and results in XIAP*Smac complexes at or within
mitochondria that are too large to diffuse through Bax/Bak
pores and might even block them for further Smac–XIAP
interaction. Our biochemical data also indicated that a
seemingly disproportionate amount of Smac was sealed off
from cytosolic ubiquitination and degradation processes. The
cytosolic caspase-inhibitory potential of XIAP thus could be
significantly enhanced if the interaction of a small pool of XIAP
and Smac is sufficient to prevent further Smac release. In this
context, it is also interesting to note that the differentiation
into postmitotic/non-proliferating cells, such as neurons,
cardiomyocytes and myotube-like cells, is accompanied by
XIAP obtaining a particularly dominant role in preventing
apoptosis execution in these cells.4–6 Our findings in primary
neurons indicated that mitochondrial retention of Smac could
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contribute to the potency of XIAP in such scenarios.
Preventing Smac from entering the cytosol would also
promote apoptosis prevention beyond immediate XIAP-
mediated caspase inhibition. The binding of cytosolic Smac
to cIAPs 1 and 2 induces rapid autoubiquitination and
proteasomal degradation of Smac and cIAPs, resulting in an
NF-kB-dependent secretion of TNF-a and subsequent auto-
crine apoptosis induction.26,38,39
Taken together, our data showed that the activity of XIAP
includes a hitherto unknown function at the mitochondria: the
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selective mitochondrial retention of Smac subsequent to
MOMP. This function may strengthen the anti-apoptotic
potential of XIAP and seems of relevance for cancer cells
and postmitotic cells that express high levels of XIAP.
Materials and Methods
Materials. Recombinant soluble human ‘killer’ TRAIL and STS were from Alexis
(San Diego, CA, USA). The broad-spectrum caspase inhibitor benzyloxycarbonyl-
Val-Ala-Asp(O-methyl)-fmk (zVAD) was purchased from Bachem (St. Helen’s, UK).
Embryo-tested mineral oil and CHX as well as all other chemicals came in analytical
grade purity from Sigma-Aldrich (Tallaght, Dublin, Ireland).
Plasmids and molecular cloning. pSmac-YFP and pIMS-RP were
described before.19,40 To express C-XIAP-C, Cerulean was amplified from
pmCerulean-C120 and ligated back into pmCerulean C1 using EcoRI and SalI
restriction sites, yielding pmCerulean-2. The sequence of XIAP was amplified from
plasmid pXIAP21 by polymerase chain reaction and the product was ligated into the
EcoRI and XhoI sites of the pmCerulean2 plasmid, yielding pC-XIAP-C. Point
mutations were introduced by site-directed mutagenesis using KOD Hot Start
Polymerase (Novagen, Merck Biosciences, Nottingham, UK). Sense and antisense
primers for the different mutations were as follows:
pC-XIAP-C D148A:
50-GAACTGGGCAGGTTGTAGCTATATCAGACACCATATAC-30 and 50 GTATA
TGGTGTCTGATATAGCTACAACCTGCCCAGTTC 30;
pC-XIAP-C W310A, 50-GGAGGGCTAACTGATGCGAAGCCCAGTGAAGAC-30
and 50-GTCTTCACTGGGCTTCGCATCAGTTAGCCCTCC-30;
p-Smac-YFP (A54M):
50-GATTTGGCATGACACTGTGTATGGTTCCTATTGCTCAGAAATC-30 and
50-GATTTCTGAGCAATAGGAACCATACACAGTGTCATGCCAAATC-30.
All coding sequences were verified by sequencing.
Peptide synthesis. A peptide comprised an NH2-terminal Smac-derived IAP
antagonizing sequence (AVPIAQK), and a COOH-terminal HIV-TAT protein-
transduction domain (GRKKRRQRRRPPQ) was prepared by standard solid-phase
peptide synthesis. Single coupling cycles, using a 10-fold excess of
fluorenylmethyloxycarbonyl chloride (Fmoc)-amino acid derivatives to resin-bound
peptide were used, except for V2, R17 and P18, for which double coupling cycles
were used. Assembly of the amino acid sequence, starting from a Rink Amide
methoxybenzohydroxamic acid (MBHA) resin, was carried out on an automated
peptide synthesizer (model 433A; Applied Biosystems, Warrington, UK). Peptides
were deprotected and cleaved from the synthesis resin using a mixture of 80%
trifluoroacetic acid, 5% water, 5% tri-isopropylsilane and 10% thioanisole at 201C for
4 h. Peptides were precipitated and washed three times with 10ml portions of
diethyl ether, dried, dissolved in distilled water and lyophilized. Chromatographic
analysis and purification were performed on a BioCAD SPRINT Perfusion
Chromatography Workstation (PerSeptive Biosystems, Framingham, MN, USA)
using Gemini columns (Phenomenex, Torrance, CA, USA). Purified peptides were
finally characterized by MALDITOF mass spectrometry using an a-cyano-4-
hydroxy-cinnamic acid matrix.
Cell culture and transfection. Human cancer cell lines were cultured in
RPMI-1640 medium supplemented with penicillin (100mg/ml), streptomycin
(100mg/ml) and 10% heat-inactivated fetal calf serum (Sigma-Aldrich) at 371C
and 5% CO2. For transfection, 0.5mg of plasmid DNA and 1 ml Turbofect
(Fermentas GmbH, St Leon Rot, Germany) were incubated in 100 ml of serum-free
medium for 20min at room temperature. The transfection mix was added dropwise
to 1 ml culture media and left on the cells at 371C overnight. MCF-7 and HeLa cells
stably expressing Smac-YFP or cyt-c-GFP were described before.19 For the
isolation of mouse cortical neurons, C57BL6 mouse neocortex was isolated from
embryos at gestation day 16. The isolated tissue was transferred to dissection
medium on ice (phosphate-buffered saline (PBS) with 0.25% glucose, 0.3% BSA)
and incubated with trypsin-EDTA (0.25%) at 371C for 15min and neurons were
dissociated by gentle pipetting after centrifugation (400 g for 3 min). Neurons
were re-suspended in fresh plating medium (MEM containing 5% fetal calf serum,
5% horse serum, 100 U/ml penicillin/streptomycin, 0.5 mM L-glutamine and 0.6% D-
glucose) and plated in dishes. Plating medium was exchanged for embryonic
neurobasal medium (Invitrogen, Paisley, UK) containing 100 U/ml of penicillin/
streptomycin, 2% B27 (Invitrogen), 0.5 mM L-glutamine and 600 nM cytosine
arabinofuranoside (Sigma) the following day. One-third of the medium was
exchanged for fresh medium every 2to 3 days. Neurons were transfected on days
4–7 with pSmac-YFP using Lipofectamine 2000 (Invitrogen) as per the
manufacturer’s instructions. Ethical approval was provided by the Royal College
of Surgeons in Ireland for all animal work carried out within this study.
Immunoprecipitation. For immunoprecipitation studies, cells were cultivated
in a T75 culture flask in 12ml of medium and grown to 80% confluency. Cells were
transfected with pmCerulean-C1, pC-XIAP-C or pSmac-YFP as described above.
Cells were trypsinized and collected at 1000 r.p.m. for 3 min and washed with PBS.
The cell pellet was resuspended in NP-40 lysis buffer (50mM Tris-HCl pH 8.0,
150mM NaCl, 1% NP-40, 0.5 M EDTA and protease inhibitor cocktail 1 : 100) and
homogenized with a needle and syringe. Samples were first incubated overnight at
41C with 5 mg rabbit polyclonal Smac antibody (AF-789, R&D Systems,
Minneapolis, MN, USA) or 5 mg anti-rabbit IgG antibody (control), then incubated
with anti-rabbit peroxidase-conjugated secondary antibody (Jackson Laboratories,
Bar Harbor, ME, USA) for 1 h at 41C and finally incubated with protein A/G agarose
beads (Santa Cruz Biotechnology, Santa Cruz, CA, USA) for 2 h at 41C. The
protein–bead complex was collected by centrifugation, boiled and samples were
subjected to western blotting.
Preparation of whole cell extracts, cell fractionation andwestern
blotting. For whole cell extracts, cells were collected at 400 g for 3 min and
washed with PBS. To analyze the release of Smac, cells were fractioned into
cytosolic extracts and pellets by selective plasma membrane permeabilization using
permeablization buffer (20mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid
(HEPES) pH 7.4, 10mM KCl, 1.5 mM MgCl2, 1 mM EDTA, 250 nM sucrose and
100mg/ml digitonin) as described before.19 Cell pellets, cytosolic cell extracts or
whole cell extracts were re-suspended in lysis buffer (62.5mM Tris-HCl, pH 6.8,
10% (v/v) glycerin, 2% (w/v) SDS, 1 mM phenylmethylsulfonyl fluoride, 1 mg/ml
pepstatin A, 1 mg/ml leupeptin and 5 mg/ml aprotinin) and heated at 951C for 20min.
Protein content was determined using Pierce Micro-BCA protein assay (Pierce,
Northumberland, UK). An equal amount of protein (20 mg) was loaded onto
SDS-polyacrylamide gels. Proteins were separated at 100 V for 2.5 h and then
blotted to nitrocellulose membranes (Protean BA 83; 2 mm; Schleicher & Schuell,
Whatman, Kent, UK) in transfer buffer (25mM Tris, 192mM glycine, 20% methanol
(v/v) and 0.01% SDS) at 18 V for 60min. The blots were blocked with 5% nonfat dry
milk in TBST (15mM Tris-HCl, pH 7.5, 200mM NaCl and 0.1% Tween 20) at room
temperature for 1 h. Membranes were incubated with the following antibodies: a
Figure 8 Plasma membrane permeabilization causes rapid cytosolic depletion of XIAP and re-establishes Smac release. (a) Representative images of the response of an
untreated MCF-7 Smac-YFP cell to digitonin-based plasma membrane permeabilization. Upon permeabilization, C-XIAP-C fluorescence was lost from the cytosol.
Mitochondrial Smac-YFP fluorescence did not noticeably change. Scale bar¼ 10mm. (b) Representative images of the response of a TRAIL/CHX pre-treated MCF-7 Smac-
YFP cell to digitonin-based plasma membrane permeabilization. Upon permeabilization, C-XIAP-C fluorescence was lost from the cytosol. Mitochondrial Smac-YFP was lost in
parallel. Scale bar¼ 10mm. (c, d) Temporal profiles of Smac-YFP and C-XIAP-C release in untreated (c) or TRAIL/CHX pre-treated (d) MCF-7 Smac-YFP cells. Smac-YFP
release was plotted as the change in cellular fluorescence S.D., C-XIAP-C loss was plotted as the change in cellular fluorescence intensity. Two representative cells are shown
each. Release onset was set to time zero. A total of n¼ 4 untreated cells or n¼ 8 pre-treated cells from three experiments each were analysed. (e) Comparison of amounts of
Smac-YFP released after permeabilization of untreated or TRAIL/CHX pre-treated cells expressing C-XIAP-C. Cellular fluorescence S.D. for 4 and 8 cells per group were
compared at 5min after onset of C-XIAP-C loss. Error bars represent S.E.M. *Po0.05 (Student’s t-test). (f) Mitochondrial Smac retention cannot be detected by biochemical
fractionation. MCF-7 cells transfected to express Cerulean or C-XIAP-C were treated with TRAIL/CHX for the indicated times and subjected to digitonin-based biochemical
fractionation. Smac release was detected by immunoblotting. Longer exposures were used to detect signals corresponding to poly-ubiquitinated Smac (calculated molecular
weights of 44 and 52.5 kDa, respectively). Porin and a-tubulin served as loading controls. Experiment was repeated eight times with similar results
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mouse monoclonal XIAP antibody (610763, clone 48; BD Transduction
Laboratories, San Jose, CA, USA); a rabbit polyclonal GFP antibody (PC 408;
Calbiochem, Merck, Darmstadt, Germany); a mouse monoclonal a-tubulin antibody
(Sigma); a rabbit polyclonal Smac antibody (AF-789, R&D Systems); or a mouse
monoclonal porin antibody (Sigma). Membranes were washed with TBST three
times for 5min and incubated with anti-mouse or anti-rabbit peroxidase-conjugated
secondary antibodies (Jackson Laboratories) for 1 h. Blots were washed and
developed using the enhanced chemiluminescence detection reagent (Millipore,
Cork, Ireland). Chemiluminescence was detected at 12-bit dynamic range using a
Fuji LAS 4000 CCD system (Fujifilm UK Ltd., Bedfordshire, UK).
Flow cytometry. Flow cytometry was performed on a Partec Cyflow ML16 flow
cytometer (Partec, Mu¨nster, Germany) equipped with a 488-nm argon ion laser,
532-nm diode laser and a 405-nm diode laser. In all, 10 000 gated events were
acquired for each sample. For cell death analysis, cells were incubated in binding
buffer (10mM HEPES, 135mM NaCl and 5mM CaCl2) containing Annexin-V
fluorescein isothiocyanate (FITC) conjugate (5 ml/ml) (BioVision, Mountain View,
CA, USA) and propidium iodide (PI; 1 mg/ml) at 371C for 15min. Cells were
re-suspended in ice-cold binding buffer and analysed. Cells were excited with the
405 nm laser to identify cells positively transfected with pCerulean, pCerulean/
pXIAP or pC-XIAP-C. Cerulean fluorescence was collected through a 455 nm band-
pass filter. FITC was exited with the 488 nm laser and fluorescence emission was
collected through a 520-nm band-pass filter; PI was excited with the 488 nm laser
and fluorescence emission was collected through a 620-nm long pass filter.
Samples were analyzed using Flowmax software (Partec).
Live cell microscopy and digital imaging. Cells were cultivated on
glass bottom dishes (Willco BV, Amsterdam, The Netherlands) in 200ml of medium
at least overnight to let them attach firmly. For MCF-7 cell proliferation analysis,
24 h after transfection, images were taken using a Nikon TE 300 equipped with a
 20, NA 0.45 phase contrast objective and a CCD camera (SPOT RT SE 6;
Diagnostic Instruments, Sterling Heights, MI, USA) using the appropriate CFP filter
sets (excitation 436±10 nm and emission 480±20 nm). To quantify cell
proliferation, identical regions were re-examined every 24 h.
For time-lapse imaging of human cancer cells, the culture media was buffered
with HEPES (10mM, pH 7.4) and covered with mineral oil. Apoptosis was induced
on stage with 1 mM STS or 100 ng/ml TRAIL plus 1 mg/ml CHX. For the imaging
of mouse cortical neurons, the culture medium was exchanged for imaging
buffer (120mM NaCl, 3.5 mM KCl, 0.4 mM KH2PO4, 20mM HEPES, 5 mM
NaHCO3, 1.2 mM Na2SO4, 1.2 mM CaCl2, 1.2 mM MgCl2 and 15mM glucose; pH
7.4). IAP-antagonizing peptide (AVPIAQKGRKKRRQRRRPPQ) was added at
a final concentration of 100mM 2 h before addition of 300 nM STS. Control
experiments verified non-toxicity of peptide and excluded phototoxicity of the
imaging procedure. Cells were monitored confocally using an LSM 5 live
microscope (Carl Zeiss MicroImaging, Inc., Jena, Germany) equipped with a  40
oil fluorescence objective and a temperature-controlled incubation chamber. The
confocal laser scanning unit was equipped with a 405-nm argon laser (CFP
excitation), a 489-nm argon laser (YFP/GFP excitation) and a 561-nm argon laser
(RFP excitation). Images were analysed using Metamorph software (Molecular
Devices, Coventry, UK). The release kinetics of cyt-c or Smac were shown as S.D.
from the average pixel intensity of individual cells. Compartmentalized cyt-c-GFP or
Smac-YFP contributes to a high S.D. and homogeneously distributed cyt-c-GFP
or Smac-YFP was represented by a low S.D. Baselines before the release were
scaled to 100%.
On stage plasma membrane permeabilization. MCF-7 Smac-YFP
cells expressing C-XIAP-C were pre-treated with 100 ng/ml TRAIL/1mg/ml CHX or
vehicle for 4 h. C-XIAP-C and Smac-YFP images were then acquired confocally at
20 s temporal resolution. To permeabilize the plasma membrane, 100ml of media
was replaced with 100ml of permeabilization buffer (20mM HEPES, 10mM KCl,
1.5 mMMgCl2, 1 mM EDTA, 250 nM sucrose and 100 mg/ml digitonin). The confocal
plane was chosen close to the glass coverslip surface to minimize mitochondrial
movements upon plasma membrane permeabilization. Images were analysed using
Metamorph software.
Immunofluorescence staining. Cells were cultivated on eight-well
chamber slides (Ibidi, Integrated Biodiagnostics, Martinsried, (Munich), Germany)
in 200 ml of medium. Cells were treated with 1 mM STS or 100 ng/ml TRAIL plus
1mg/ml CHX. After 4 h of treatment, cells were fixed with 4% paraformaldehyde for
20min at room temperature. Cells were permeabilized for 3min using 0.1% Triton
X-100 in ice-cold PBS. Cells were washed in PBS and blocked in 5% horse serum,
0.3% Triton X-100 in PBS for 1 h at room temperature. Cells were once again
washed in PBS and incubated in primary antibodies (a mouse monoclonal cyt-c
antibody (55432, BD Biosciences) and a rabbit polyclonal Smac antibody (AF-789;
R&D Systems)) at a dilution of 1 : 500 overnight at 41C. Cells were washed in PBS
and the secondary antibodies (FITC-conjugated anti-rabbit IgG, Rhodamine-
conjugated anti-mouse IgG; Jackson Laboratories) were applied for 1 h at room
temperature, at a dilution of 1 : 2000. Cells were washed once again in PBS and
imaged at 12-bit dynamic range using an LSM 710 confocal microscope (Carl
Zeiss). The laser scanning unit was equipped with a 405-nm argon laser (CFP
excitation), a 488-nm argon laser (FITC excitation) and a 543-nm argon laser
(Rhodamine excitation). For edge detection, raw images were processed using the
‘find edges’ algorithm in ImageJ 1.42i (National Institute of Mental Health, MD, USA).
Statistics. Data are given as means±S.D. or S.E.M. For statistical comparison,
Student’s t-test or ANOVA and subsequent Tukey’s test were used for normally
distributed data. The P-values ofo0.05 were considered to be statistically significant.
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